Skip to main content
Top

Navigating discordant findings in multimodality imaging of prostate cancer in the MRI and PSMA-PET era

Abstract

Various imaging modalities play key roles throughout the different stages of prostate cancer. Each imaging modality has different strengths and weaknesses and various scoring systems or frameworks are used to interpret their findings. Discordances between imaging modalities or interpretation frameworks, and even with clinicopathological findings are not uncommon. Discordances often lead to challenges in the decision-making process, especially with dynamically changing indications for newer imaging modalities. While more research is needed on harmonizing interpretations across different modalities, multidisciplinary team discussion is key to optimizing management of patients with prostate cancer when such discordances are present. In this comprehensive review, we take a deep dive in to these various discordances seen in clinical practice and explore their clinical implications.
Title
Navigating discordant findings in multimodality imaging of prostate cancer in the MRI and PSMA-PET era
Authors
Sungmin Woo
Benedetta Masci
Anton S. Becker
Angela Tong
Kent P. Friedman
Felipe de Galiza Barbosa
Damiano Caruso
Andrea Laghi
Hebert Alberto Vargas
Publication date
03-11-2025
Publisher
Springer Milan
Published in
La radiologia medica
Print ISSN: 0033-8362
Electronic ISSN: 1826-6983
DOI
https://doi.org/10.1007/s11547-025-02140-6
This content is only visible if you are logged in and have the appropriate permissions.

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

0.5 AMA PRA Category 1 Credit(s)

Our experts explore using biomarker tests and interpreting results, establishing a shared decision-making approach with patients and caregivers, and applying biomarker testing to guide treatment strategies.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Learn more

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Learn more
Image Credits
Alzheimer’s disease in the biomarker era: preparing the multidisciplinary care team/© Springer Healthcare IME, Navigating neuroimaging in Alzheimer’s care: Practical applications and strategies for integration/© Springer Healthcare IME